Op0036 methotrexate and Rheumatoid Arthritis Associated Interstitial Lung Disease

Juge, Pierre-Antoine; Lee, Joyce; Lau, Julie S.; Kawano, L.; Rojas-Serrano, Jorge; Sebastiani, Marco; Koduri, Gouri; Matteson, E.; Bonfiglioli, Karina Rossi; Sawamura, Márcio Valente Yamada; Kairalla, Ronaldo Adib; Cavagna, Lorenzo; Cassione, Emanuele Bozzalla; Manfredi, Andreina; Mejía, Mayra; Henríquez, Pedro Rodríguez; González-Pérez, Montserrat I.; Falfán-Valencia, Ramcés; Buendía-Roldán, Ivette; Pérez-Rubio, Gloría; Ebstein, Esther; Gazal, Steven; Borie, R.; Ottaviani, Sébastien; Kannengiesser, Caroline; Wallaert, B.; Uzunhan, Y.; Nunès, Hilario; Valeyre, Dominique; Kermanac’h, Nathalie Saidenberg; Mc, Boissier; Stervinou, L. Wemeau; Flipo, René‐Marc; Marchand-Adam, S.; Richette, Pascal; Allanore, Yannick; Dromer, C.; Truchetet, Marie-Élise; Richez, Christophe; Schaeverbeke, Thierry; Lioté, H.; Thabut, Gabriel; Deane, Kevin D.; Solomon, Joshua J.; Doyle, Tracy J.; Ryu, Jay H.; Rosas, Iván O.; Holers, V. Michael; Boileau, Cathérine; Debray, Marie‐Pierre; Porcher, Raphaël; Schwartz, David A.; Vassallo, Robert; Crestani, Bruno; Dieudé, Philippe

doi:10.1136/annrheumdis-2020-eular.1678

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the medication used, no significant difference was found in MTX group (ORs =0.84, 95% CI 0.56–1.27, Figure 18B [ 32 , 34 , 35 , 37 , 38 , 46 , 47 ]; HRs = 1.02, 95%CI 0.83–1.27, Figure 18A [ 10 , 19 , 20 , 33 , 36 , 43 ]). The use of LEF was reported a substantial correlation with prevalence (ORs = 1.42, 95%CI 1.08–1.87; p < 0.05, Figure 19 )[ 32 , 38 , 46 , 47 ].…”

Section: Resultsmentioning

confidence: 99%

The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Wang,

et al. 2024

Annals of Medicine

View full text Add to dashboard Cite

Background Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). Existing knowledge on the prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is inconclusive. Therefore, we designed this review to address this gap. Materials and Methods To find relevant observational studies discussing the prevalence and/or risk factors of RA-ILD, EMBASE, Web of Science, PubMed, and the Cochrane Library were explored. The pooled odds ratios (ORs) / hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated with a fixed/ random effects model. While subgroup analysis, meta-regression analysis and sensitivity analysis were carried out to determine the sources of heterogeneity, the I 2 statistic was utilized to assess between-studies heterogeneity. Funnel plots and Egger’s test were employed to assess publication bias. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, our review was conducted. Results A total of 56 studies with 11,851 RA-ILD patients were included in this meta-analysis. The pooled prevalence of RA-ILD was 18.7% (95% CI 15.8–21.6) with significant heterogeneity ( I 2 = 96.4%). The prevalence of RA-ILD was found to be more likely as a result of several identified factors, including male sex (ORs = 1.92 95% CI 1.70–2.16), older age (WMDs = 6.89, 95% CI 3.10–10.67), having a smoking history (ORs =1.91, 95% CI 1.48–2.47), pulmonary comorbidities predicted (HRs = 2.08, 95% CI 1.89–2.30), longer RA duration (ORs = 1.03, 95% CI 1.01–1.05), older age of RA onset (WMDs =4.46, 95% CI 0.63–8.29), positive RF (HRs = 1.15, 95%CI 0.75-1.77; ORs = 2.11, 95%CI 1.65–2.68), positive ACPA (ORs = 2.11, 95%CI 1.65–2.68), higher ESR (ORs = 1.008, 95%CI 1.002–1.014), moderate and high DAS28 (≥3.2) (ORs = 1.87, 95%CI 1.36–2.58), rheumatoid nodules (ORs = 1.87, 95% CI 1.18-2.98), LEF use (ORs = 1.42, 95%CI 1.08–1.87) and steroid use (HRs= 1.70, 1.13–2.55). The use of biological agents was a protective factor (HRs = 0.77, 95% CI 0.69–0.87). Conclusion(s) The pooled prevalence of RA-ILD in our study was approximately 18.7%. Furthermore, we identified 13 risk factors for RA-ILD, including male sex, older age, having a smoking history, pulmonary comorbidities, older age of RA onset, longer RA duration, positive RF, positive ACPA, higher ESR, moderate and high DAS28 (≥3.2), rheumatoid nodules, LEF use and steroid use. Additionally, biological agents use was a protective factor.

show abstract

Section: Resultsmentioning

confidence: 99%

The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Wang,

et al. 2024

Annals of Medicine

View full text Add to dashboard Cite

show abstract

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be

Goos

Sadeleer

Yserbyt

et al. 2021

JCM

View full text Add to dashboard Cite

A significant proportion of patients with interstitial lung disease (ILD) may develop a progressive fibrosing phenotype characterized by worsening of symptoms and pulmonary function, progressive fibrosis on chest computed tomography and increased mortality. The clinical course in these patients mimics the relentless progressiveness of idiopathic pulmonary fibrosis (IPF). Common pathophysiological mechanisms such as a shared genetic susceptibility and a common downstream pathway—self-sustaining fibroproliferation—support the concept of a progressive fibrosing phenotype, which is applicable to a broad range of non-IPF ILDs. While antifibrotic drugs became the standard of care in IPF, immunosuppressive agents are still the mainstay of treatment in non-IPF fibrosing ILD (F-ILD). However, recently, randomized placebo-controlled trials have demonstrated the efficacy and safety of antifibrotic treatment in systemic sclerosis-associated F-ILD and a broad range of F-ILDs with a progressive phenotype. This review summarizes the current pharmacological management and highlights the unmet needs in patients with non-IPF ILD.

show abstract

Op0036 methotrexate and Rheumatoid Arthritis Associated Interstitial Lung Disease

Cited by 2 publications

References 0 publications

The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be

Contact Info

Product

Resources

About